Nasdaq
$0.1656▲ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $16.2MShares out 98.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 10.16After-hours26.10.17 05:028-KKey event#●●●#●●●
aTYR PHARMA INC
aTYR Pharma held a special meeting of stockholders on October 16, 2026, where shareholders approved a proposal for a reverse stock split. The board of directors is now authorized to implement a reverse stock split at a ratio ranging from 1-for-10 to 1-for-50.…more
$0.1656+0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Pre-market26.10.07 20:18SCHEDULE 13G/AOwnership
aTYR PHARMA INC
Federated Hermes, Inc. and its affiliates filed a Schedule 13G regarding their interest in aTyr Pharma, Inc. shares. While the reporting persons act as investment advisers with voting power over the shares held by their managed funds, they expressly disclaim beneficial ownership of the securities.…more
$0.1656+0.12%vs prev closeView filingShare - 10.1After-hours26.10.02 05:034Ownership
aTYR PHARMA INC
Insider Brandon Yaras of aTYR PHARMA INC filed a report regarding changes in beneficial ownership of securities on October 1, 2026. This filing serves as a standard disclosure of the insider's equity position changes.…more
$0.1656+0.12%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:00#●●●#●●●
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma has entered into a research collaboration with Montefiore Einstein to study its monoclonal antibody ATYR2810 in pediatric osteosarcoma. This is an early-stage research initiative and does not involve immediate clinical trial results or commercial revenue.…more
$0.1656+0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.13Pre-market26.10.13 21:00
●●●●●●●● ●●●●● ●●●●●●
aTyr Pharma announced the publication of research in the Journal of Biological Chemistry demonstrating the anti-fibrotic effects of its drug candidate ATYR0101. The company is currently conducting IND-enabling studies and expects to advance the candidate into clinical trials in 2027.…more
$0.1656+0.12%vs prev close - 9.24Regular26.09.25 02:31
●●●●●●●● ●●●●● ●●●●●●
aTyr Pharma has reached a formal agreement with the FDA regarding the Phase 3 clinical trial protocol for its lead candidate, efzofitimod. Despite this regulatory progress, the company requires additional capital to fund the study and is currently trading near its 52-week low.…more
$0.1656+0.12%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report